An ongoing phase IB/II trial (NCT02501096), is assessing the maximum tolerated dose of lenvatinib combined with the PD-1 inhibitor pembrolizumab in patients with solid tumors, including thyroid cancer [77]. This evidence concerns the gene PDCD1 and thyroid gland carcinoma.